Molecular Cancer

Article	Citations
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives	837
Circular RNA: metabolism, functions and interactions with proteins	600
mRNA vaccine for cancer immunotherapy	492
Targeting STAT3 in Cancer Immunotherapy	482
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions	476
The cancer metabolic reprogramming and immune response	452
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance	440
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects	403
Natural killer cells in cancer biology and therapy	383
Glioma targeted therapy: insight into future of molecular approaches	322
Targeting TGF-β signal transduction for fibrosis and cancer therapy	317
Exosomes as a new frontier of cancer liquid biopsy	316
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments	276
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target	274
Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-β1 axis	274
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy	269
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities	269
Exosome-based immunotherapy: a promising approach for cancer treatment	262
G-quadruplexes: a promising target for cancer therapy	262
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities	258
The role of m6A RNA methylation in cancer metabolism	249
LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes	235
The role of ubiquitination and deubiquitination in cancer metabolism	212
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc	205
mRNA vaccine: a potential therapeutic strategy	204

CircRNA inhibits DNA damage repair by interacting with host gene	202
Lung cancer immunotherapy: progress, pitfalls, and promises	201
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments	198
Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies	188
mRNA therapeutics in cancer immunotherapy	182
Cuproptosis: mechanisms and links with cancers	177
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine	176
m6A modification: recent advances, anticancer targeted drug discovery and beyond	176
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer	174
Long noncoding RNAs: functions and mechanisms in colon cancer	174
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling	172
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer	172
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1	170
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	166
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer	162
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer	158
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer	152
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer	147
Novel insights into the interplay between m6A modification and noncoding RNAs in cancer	147
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook	146
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	143
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer	142
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer	142
circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2	140
cGAS-STING pathway in cancer biotherapy	138
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	134
Cancer associated-fibroblast-derived exosomes in cancer progression	134
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy	129
The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation	128
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	127
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	124
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	119
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	118
Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis	118
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy	114
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	114
Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit	113
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	112
CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc	111
Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis	109
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer	109
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM	105
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances	105
Proteolysis-targeting chimeras (PROTACs) in cancer therapy	104
Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis	104
DDX3X: structure, physiologic functions and cancer	103
Targeting the RNA m6A modification for cancer immunotherapy	102
Insights into N6-methyladenosine and programmed cell death in cancer	98
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development	98
Non-coding RNAs regulation of macrophage polarization in cancer	98

Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer	98
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	96
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab	96
circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway	95
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis	95
Advancements in nanoparticle-based treatment approaches for skin cancer therapy	94
Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer	94
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation	93
Proteomics technologies for cancer liquid biopsies	91
Targeting the tumor stroma for cancer therapy	91
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	91
Clinical and immunological effects of mRNA vaccines in malignant diseases	90
Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification	89
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer	89
Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms	89
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study	88
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction	87
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development	87
M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma	85
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma	85
Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin	85
CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression	85
The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway	84
CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability	83
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy	83
CircRNAs: biogenesis, functions, and role in drug-resistant Tumours	82
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression	80
Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy	80
Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer	78
Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications	78
Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?	77
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies	77
Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis	75
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer	75
Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications	74
Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma	74
CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing	74
Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling	73
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma	73
Targeting KRAS mutant cancers: from druggable therapy to drug resistance	73
Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p	73
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential	72
The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis	72
CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway	71
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	71
FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2	71
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p	71
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer	70
ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma	69
CircRNAs in anticancer drug resistance: recent advances and future potential	68
Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types	68
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer	68
Delivery of cancer therapies by synthetic and bio-inspired nanovectors	67
Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling	67
A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma	67
CD39/CD73/A2AR pathway and cancer immunotherapy	66
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors	66
circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis	65
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment	65
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma	65
Molecular mechanisms of tumor resistance to radiotherapy	64
Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2	64
CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma	63
Histone citrullination: a new target for tumors	63
The journey of CAR-T therapy in hematological malignancies	63
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance	63
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer	63
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers	62
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway	62
β-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer	62
Potential clinical utility of liquid biopsies in ovarian cancer	62
m6A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling	62
Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy	61
Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy	61
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	61
The role and application of small extracellular vesicles in gastric cancer	60
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer	60
Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis	59
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades	59
A clinician’s handbook for using ctDNA throughout the patient journey	58

Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing	58
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	58
The potential roles of exosomes in pancreatic cancer initiation and metastasis	58
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	57
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p	57
The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer	57
The functional roles of the circRNA/Wnt axis in cancer	55
A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer	55
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	55
Clinical significance of FBXW7 loss of function in human cancers	55
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers	55
A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3	55
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy	55
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes	54
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer	54
Regulatory cells and the effect of cancer immunotherapy	53
Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling	53
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses	53
RNA-based therapies: A cog in the wheel of lung cancer defense	53
CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner	53
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	52
CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma	52
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis	52
Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA	52
The involvement of exosomes in the diagnosis and treatment of pancreatic cancer	52
circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling	52
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	51
CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer	51
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	50
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion	50
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells	50
Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients	50
Circular RNAs’ cap-independent translation protein and its roles in carcinomas	50
Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer	49
mRNA in cancer immunotherapy: beyond a source of antigen	49
Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer	49
NK cells and solid tumors: therapeutic potential and persisting obstacles	49
Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis	49
The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma	48
CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis	48
Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas	48
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy	47
Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma	47
CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA	47
Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	47
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	47
Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10	46
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation	46
Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer	46
Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication	46
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy	45
Clinical considerations for the design of PROTACs in cancer	45
Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1	45
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression	45
Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma	45
Tumor-suppressive circRHOBTB3 is excreted out of cells via exosome to sustain colorectal cancer cell fitness	44
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges	44
N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma	44
Nonsense-mediated RNA decay and its bipolar function in cancer	44
Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer	43
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers	43
Using single-cell sequencing technology to detect circulating tumor cells in solid tumors	42
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions	42
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy	42
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis	41
CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity	41
Characterization of distinct circular RNA signatures in solid tumors	40
The intersection of COVID-19 and cancer: signaling pathways and treatment implications	40
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance	40
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer	40
CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein	40
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2	40
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial	40
RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics	40
Clinical application and detection techniques of liquid biopsy in gastric cancer	40
AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway	39
A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2–10 ng/mL at initial biopsy	39
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma	39
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	39
Nanomaterials in tumor immunotherapy: new strategies and challenges	38
The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway	38
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1	38
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development	38
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma	37
Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer	37
Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer	37
Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1	36
CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer	35
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?	35
A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study	35
Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop	35
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma	34
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials	34
Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation	34
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade	34